Yahoo Finance53m
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) ...
Worldcrunch on MSN2d
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s
The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
Medscape2d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Armed robbery in Revesby5h
Finger Prick On Track To Become Alzheimer's Test
A quick finger prick and a few drops of blood on a card that can be sent in regular mail. This approach could soon make ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
The Florida Times-Union5d
Alzheimer's is life-changing for 'everyone around them'; Jacksonville walkers show support
The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...
NL Times1d
New Alzheimer's drug: only a few eligible for treatment
It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...